Flexion Therapeutics (NASDAQ:FLXN) is scheduled to post its quarterly earnings results after the market closes on Thursday, February 28th. Analysts expect Flexion Therapeutics to post earnings of ($1.24) per share for the quarter.
Flexion Therapeutics stock opened at $14.28 on Thursday. The firm has a market capitalization of $542.11 million, a P/E ratio of -3.43 and a beta of 1.74. Flexion Therapeutics has a 52 week low of $10.98 and a 52 week high of $29.10. The company has a quick ratio of 8.74, a current ratio of 8.88 and a debt-to-equity ratio of 1.02.
Several equities analysts recently commented on the company. Zacks Investment Research lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 target price (down from $42.00) on shares of Flexion Therapeutics in a research note on Friday, January 4th. Benchmark lowered Flexion Therapeutics from a “buy” rating to a “hold” rating and set a $11.49 target price for the company. in a research note on Friday, January 4th. BMO Capital Markets dropped their target price on Flexion Therapeutics from $36.00 to $34.00 and set an “outperform” rating for the company in a research note on Friday, January 4th. Finally, ValuEngine upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $24.10.
In other Flexion Therapeutics news, insider Michael D. Clayman sold 3,278 shares of the company’s stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $12.36, for a total transaction of $40,516.08. Following the completion of the sale, the insider now directly owns 64,782 shares in the company, valued at $800,705.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.59% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://macondaily.com/2019/02/21/flexion-therapeutics-flxn-set-to-announce-earnings-on-thursday.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.